Last updated on February 2018

uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer

Brief description of study

uPAR PET/CT for Staging Advanced and Localised oral and oropharyngeal cancer

Detailed Study Description

To compare the diagnostic value of uPAR-PET/CT for prognostication compared to the current imaging options (CT, MRI and ultrasound) by observer-blinded readings. The reference that will be used as "gold standard" is the pathological examination of the surgically removed tissues.

The new imaging modality (uPAR-PET/CT) will be used in two separate groups of patients with head and neck cancer:

Study I:

Patients with oral cancer without clinical evidence of spread (OSCC in stage cN0)

Study II:

Patients with metastatic oral cancer (OSCC in stage cN +) and patients with metastatic oropharyngeal cancer (OPSCC in stage cN +).

Clinical Study Identifier: NCT02960724

Find a site near you

Start Over